Nonsurgical management of hyperhidrosis.

Area of Science:

• Dermatology
• Medical Therapeutics

Background:

• Primary focal hyperhidrosis (HH) significantly impairs quality of life, often leading patients to delay seeking medical advice.
• Patients experience functional and psychosocial disability due to HH affecting areas like axillae, palms, soles, and face.

Purpose of the Study:

• To review the treatment landscape for focal hyperhidrosis, emphasizing a stepwise approach from conservative to advanced therapies.
• To highlight the efficacy and safety of botulinum toxin (BTX) injections as a minimally invasive treatment for moderate to severe HH.

Main Methods:

• Review of conservative treatments including topical therapies (e.g., AlCl3-6H2O) and iontophoresis.
• Evaluation of minimally invasive intradermal botulinum toxin (BTX) injections (BTX-A and BTX-B) for severe HH.
• Consideration of oral medications like glycopyrrolate as adjunct or standalone therapy.

Main Results:

• Conservative measures are recommended first, but severe HH (HDSS score 3-4) may respond better to BTX.
• Intradermal BTX injections demonstrate significant improvement, acting as a safe, efficacious, quick-acting, and long-lasting intermediate treatment.
• BTX-B shows promise, while oral medications have common side effects and require caution in high-risk patients.

Conclusions:

• Treatment for focal HH should be individualized based on severity, location, and patient expectations.
• Botulinum toxin injections represent a revolutionary advancement in managing focal hyperhidrosis.
• Regular assessment and adjustment of therapy are critical for achieving optimal patient outcomes.